JP2023093495A5 - - Google Patents

Download PDF

Info

Publication number
JP2023093495A5
JP2023093495A5 JP2023054891A JP2023054891A JP2023093495A5 JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5 JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023054891 A JP2023054891 A JP 2023054891A JP 2023093495 A5 JP2023093495 A5 JP 2023093495A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sequence
phosphoinositide
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023054891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023093495A (ja
Filing date
Publication date
Priority claimed from JP2021059383A external-priority patent/JP2021113194A/ja
Application filed filed Critical
Publication of JP2023093495A publication Critical patent/JP2023093495A/ja
Publication of JP2023093495A5 publication Critical patent/JP2023093495A5/ja
Priority to JP2025093012A priority Critical patent/JP2025131697A/ja
Pending legal-status Critical Current

Links

JP2023054891A 2015-08-21 2023-03-30 組み合わせおよびその使用 Pending JP2023093495A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093012A JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15181925.7 2015-08-21
EP15181925 2015-08-21
JP2021059383A JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021059383A Division JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093012A Division JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Publications (2)

Publication Number Publication Date
JP2023093495A JP2023093495A (ja) 2023-07-04
JP2023093495A5 true JP2023093495A5 (https=) 2023-11-22

Family

ID=54010888

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018508728A Active JP6862422B2 (ja) 2015-08-21 2016-08-18 組み合わせおよびその使用
JP2021059383A Pending JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用
JP2023054891A Pending JP2023093495A (ja) 2015-08-21 2023-03-30 組み合わせおよびその使用
JP2025093012A Pending JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018508728A Active JP6862422B2 (ja) 2015-08-21 2016-08-18 組み合わせおよびその使用
JP2021059383A Pending JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093012A Pending JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Country Status (23)

Country Link
US (3) US11224654B2 (https=)
EP (2) EP3954388A1 (https=)
JP (4) JP6862422B2 (https=)
KR (2) KR102786010B1 (https=)
CN (2) CN107921129B (https=)
AU (3) AU2016311136B2 (https=)
CA (1) CA2995738A1 (https=)
CY (1) CY1124706T1 (https=)
DK (1) DK3337506T3 (https=)
ES (1) ES2891336T3 (https=)
HR (1) HRP20211291T1 (https=)
HU (1) HUE056408T2 (https=)
IL (2) IL257345B2 (https=)
LT (1) LT3337506T (https=)
MX (2) MX392561B (https=)
PL (1) PL3337506T3 (https=)
PT (1) PT3337506T (https=)
RS (1) RS62260B1 (https=)
RU (1) RU2767063C2 (https=)
SI (1) SI3337506T1 (https=)
SM (1) SMT202100541T1 (https=)
WO (1) WO2017032679A1 (https=)
ZA (1) ZA201801052B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767063C2 (ru) 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
EA202090020A1 (ru) 2017-07-10 2020-04-28 Интернэшнл - Драг - Дивелопмент - Байотек Лечение b-клеточных злокачественных новообразований с использованием афукозилированных проапоптотических анти-cd19 антител в сочетании с анти-cd20 антителами или химиотерапевтическими средствами
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220104176A (ko) * 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
EP4251138A1 (en) * 2020-11-30 2023-10-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
CA3255552A1 (en) * 2021-12-22 2023-06-29 Incyte Corporation TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
GEP20084317B (en) 2000-04-25 2008-02-25 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
RS54655B2 (sr) * 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP3581206B8 (en) * 2010-10-22 2025-02-19 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HRP20220224T1 (hr) 2011-08-16 2022-04-29 Morphosys Ag Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom
KR20140064873A (ko) * 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
NZ629684A (en) 2012-03-05 2016-10-28 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
CA2900658A1 (en) 2013-02-15 2014-08-21 3M Innovative Properties Company System and method for making pleated filter media
AU2015277516A1 (en) 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
RU2767063C2 (ru) * 2015-08-21 2022-03-16 МорфоСис АГ Комбинации и их использование
FI3916392T3 (fi) 2016-05-30 2024-06-03 Incyte Corp Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla
WO2018002031A1 (en) 2016-06-27 2018-01-04 Morphosys Ag Anti-cd19 antibody formulations
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
LT3630177T (lt) 2017-05-31 2023-10-25 Morphosys Ag Gydymo paradigma, skirta kompleksiniam gydymui anti-cd19 antikūnu ir venetoklaksu
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
AU2020267823A1 (en) 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
CN115151565A (zh) 2019-10-31 2022-10-04 莫佛塞斯公司 包含抗CD19抗体和γδT细胞的抗肿瘤组合疗法
TW202525340A (zh) 2019-10-31 2025-07-01 美商英塞特公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
KR20220104176A (ko) 2019-10-31 2022-07-26 모르포시스 아게 순차적 항-cd19 요법
WO2021259902A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
EP4251138A1 (en) 2020-11-30 2023-10-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022117799A2 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
CA3255552A1 (en) 2021-12-22 2023-06-29 Incyte Corporation TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY

Similar Documents

Publication Publication Date Title
JP2023093495A5 (https=)
RU2017143166A (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
JP2022191301A5 (https=)
JP2019533682A5 (https=)
RU2014103490A (ru) Комбинированная терапия с помощью антитела к cd19 и аналога пурина
JP2022119854A5 (https=)
RU2018107929A (ru) Комбинации и их использование
JP2017048208A5 (https=)
JP2022510964A5 (https=)
JP2017528462A5 (https=)
HRP20210838T1 (hr) Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe
JP2017507954A5 (https=)
JP2023545520A5 (https=)
JP2013542194A5 (https=)
RU2014103492A (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
JP2019519770A5 (https=)
JP2017507953A5 (https=)
FI3110440T3 (fi) Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
PE20160999A1 (es) Metodos para administrar anticuerpos anti-tnf-alfa
JP2023055904A5 (https=)
JP2024531151A5 (https=)
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
IL317199A (en) Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
RU2017137496A (ru) Средство для лечения множественной миеломы (ММ)